Compare LEXX & NXPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEXX | NXPL |
|---|---|---|
| Founded | 2004 | 1997 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 19.2M |
| IPO Year | N/A | N/A |
| Metric | LEXX | NXPL |
|---|---|---|
| Price | $0.78 | $0.72 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.50 | N/A |
| AVG Volume (30 Days) | ★ 350.9K | 85.2K |
| Earning Date | 01-13-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $522,000.00 | ★ $57,151,000.00 |
| Revenue This Year | $13.35 | N/A |
| Revenue Next Year | $78.83 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.05 | N/A |
| 52 Week Low | $0.46 | $0.43 |
| 52 Week High | $1.91 | $1.13 |
| Indicator | LEXX | NXPL |
|---|---|---|
| Relative Strength Index (RSI) | 49.91 | 59.29 |
| Support Level | $0.68 | $0.68 |
| Resistance Level | $0.86 | $0.72 |
| Average True Range (ATR) | 0.07 | 0.04 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 64.08 | 86.12 |
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
NextPlat Corp is an e-commerce and healthcare company. Its e-commerce venues form an effective network serving thousands of consumers, enterprises, and governments. Its healthcare business is focused on improving the lives of patients with complex chronic diseases through patient and provider engagement and their partnerships with payors, pharmaceutical manufacturers, and distributors, offering a broad range of solutions to address the dispensing, delivery, dosing, and reimbursement of clinically intensive, high-cost drugs. The company operates in two segments: e-Commerce Operations involves acquiring and leasing an e-commerce platform; and Healthcare Operations provides TPA, data management, COVID-19 related diagnostics and vaccinations, prescription pharmaceuticals, and Others.